Company Encyclopedia
View More
name
Menovo
603538.SH
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas.
3.157 T
603538.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking61/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.44%C
    • Profit Margin6.46%B
    • Gross Margin34.00%C
  • Growth ScoreA
    • Revenue YoY24.54%A
    • Net Profit YoY390.12%A
    • Total Assets YoY2.87%C
    • Net Assets YoY6.81%B
  • Cash ScoreA
    • Cash Flow Margin1548.60%B
    • OCF YoY24.54%A
  • Operating ScoreD
    • Turnover0.33D
  • Debt ScoreC
    • Gearing Ratio49.05%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Menovo: Net profit in the third quarter was 46.8702 million yuan, a year-on-year increase of 5.78%

    Menovo announced that its revenue for the third quarter was 439 million yuan, a year-on-year increase of 28.80%; net profit was 46.8702 million yuan, a year-on-year increase of 5.78%. Revenue for the first three quarters was 1.117 billion yuan, a year-on-year increase of 17.67%; net profit was 95.9254 million yuan, a year-on-year increase of 51.66%

    Zhitong·
    SH
    603538
    +0.45%
    Zhitong·
    SH
    603538
    +0.45%

    Menovo Pharmaceutical Gets Registration Certificate for Hypertension Drug

    Menovo Pharmaceutical Gets Registration Certificate for Hypertension Drug

    marketscreener·
    SH
    603538
    +0.45%
    marketscreener·
    SH
    603538
    +0.45%

    Menovo's subsidiary has obtained the drug registration certificate for Irbesartan and Hydrochlorothiazide tablets

    Menovo's wholly-owned subsidiary Ningbo Menovo Tiankang Pharmaceutical Co., Ltd. recently obtained the drug registration certificate for Irbesartan and Hydrochlorothiazide Tablets approved by the National Medical Products Administration. This medication is used to treat primary hypertension and combines the synergistic blood pressure-lowering effects of Irbesartan and Hydrochlorothiazide

    Zhitong·
    SH
    603538
    +0.45%
    Zhitong·
    SH
    603538
    +0.45%

    Menovo has decided not to lower the conversion price of the "Menovo Convertible Bonds" this time

    Ningbo Menovo Pharmaceutical Co., Ltd. announced that although its stock has triggered the conditions for the downward adjustment of the conversion price of the "Menovo Convertible Bonds," the board of directors has decided not to make the price adjustment. The next triggering period for the adjustment clause will restart from October 20, 2025. The bond was issued in January 2021, with an initial conversion price of RMB 37.47 per share, and investors should pay attention to the associated risks

    Zhitong·
    SH
    603538
    +0.45%
    Zhitong·
    SH
    603538
    +0.45%

    Menovo signed a strategic cooperation agreement with Shengzhao Pharmaceuticals

    Recently, Menovo officially signed a "Strategic Cooperation Agreement" with Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. According to the agreement, both parties will cooperate in areas such as technology development and transformation, production and supply chain, market expansion, and commercialization

    Zhitong·
    SH
    603538
    +0.45%
    Zhitong·
    SH
    603538
    +0.45%
    © 2025 Longbridge｜Disclaimer